Yarrow Bioscience, Inc. (YARW) stock
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30105% above fair value
$14.35+0.14 (+0.99%)
Close on Nov 18, 2026Market cap $38.31MP/E –Yield –
Yarrow Bioscience total assets
Total assets on the balance sheet at the end of each period.
Yarrow Bioscience's total assets was $23.60M at Jun 30, 2026. For fiscal 2025 it was $30.16M, down 54.9% from the year before. The highest annual figure on record is $139.93M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.16M | -54.9% |
| FY2024 | Dec 31, 2024 | $66.91M | -31.5% |
| FY2023 | Dec 31, 2023 | $97.69M | +139.7% |
| FY2022 | Dec 31, 2022 | $40.76M | -39.2% |
| FY2021 | Dec 31, 2021 | $67.05M | -28.5% |
| FY2020 | Dec 31, 2020 | $93.74M | +15.5% |
| FY2019 | Dec 31, 2019 | $81.16M | -42.0% |
| FY2018 | Dec 31, 2018 | $139.93M | +109.3% |
| FY2017 | Dec 31, 2017 | $66.87M | +59.0% |
| FY2016 | Dec 31, 2016 | $42.05M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $23.60M | -58.2% |
| Q1 FY2026 | Mar 31, 2026 | $25.87M | -61.3% |
| Q4 FY2025 | Dec 31, 2025 | $30.16M | -60.4% |
| Q2 FY2025 | Jun 30, 2025 | $44.72M | -48.4% |
| Q1 FY2025 | Mar 31, 2025 | $56.42M | -38.5% |
| Q4 FY2024 | Dec 31, 2024 | $66.91M | -31.5% |
| Q3 FY2024 | Sep 30, 2024 | $76.20M | +295.5% |
| Q2 FY2024 | Jun 30, 2024 | $86.65M | +247.2% |
| Q1 FY2024 | Mar 31, 2024 | $91.68M | +160.0% |
| Q4 FY2023 | Dec 31, 2023 | $97.69M | +139.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.27M | -58.9% |
| Q2 FY2023 | Jun 30, 2023 | $24.96M | -54.8% |
| Q1 FY2023 | Mar 31, 2023 | $35.26M | -45.2% |
| Q4 FY2022 | Dec 31, 2022 | $40.76M | -39.2% |
| Q3 FY2022 | Sep 30, 2022 | $46.91M | -42.3% |
| Q2 FY2022 | Jun 30, 2022 | $55.19M | -58.8% |
| Q1 FY2022 | Mar 31, 2022 | $64.32M | -56.9% |
| Q4 FY2021 | Dec 31, 2021 | $67.05M | -28.5% |
| Q3 FY2021 | Sep 30, 2021 | $81.32M | -24.5% |
| Q2 FY2021 | Jun 30, 2021 | $133.98M | +2.4% |
| Q1 FY2021 | Mar 31, 2021 | $149.17M | -7.1% |
| Q4 FY2020 | Dec 31, 2020 | $93.74M | +15.5% |
| Q3 FY2020 | Sep 30, 2020 | $107.68M | +11.5% |
| Q2 FY2020 | Jun 30, 2020 | $130.84M | +14.4% |
| Q1 FY2020 | Mar 31, 2020 | $160.53M | +27.1% |
| Q4 FY2019 | Dec 31, 2019 | $81.16M | -42.0% |
| Q3 FY2019 | Sep 30, 2019 | $96.58M | -37.7% |
| Q2 FY2019 | Jun 30, 2019 | $114.38M | -31.5% |
| Q1 FY2019 | Mar 31, 2019 | $126.26M | -30.0% |
| Q4 FY2018 | Dec 31, 2018 | $139.93M | +109.3% |
| Q3 FY2018 | Sep 30, 2018 | $154.96M | +268.5% |
| Q2 FY2018 | Jun 30, 2018 | $166.92M | – |
| Q1 FY2018 | Mar 31, 2018 | $180.48M | – |
| Q4 FY2017 | Dec 31, 2017 | $66.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $42.05M | – |
See a number that looks wrong?